These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16022491)

  • 21. Evaluation of sodium hyaluronate as viscous vehicle for eye drops.
    Ludwig A; Van Ooteghem M
    J Pharm Belg; 1989; 44(6):391-7. PubMed ID: 2632760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microemulsions with timolol as potential eye drops.
    Malina I; Radomska-Soukharev A
    Pharmazie; 2006 Jul; 61(7):650-1. PubMed ID: 16889077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical and physicochemical characterization of petrolatums used in eye ointment formulations.
    De Muynck C; Lalljie SP; Sandra P; De Rudder D; Van Aerde P; Remon JP
    J Pharm Pharmacol; 1993 Jun; 45(6):500-3. PubMed ID: 8103095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the Hospital Pharmacy Departments.
    Fernández-Ferreiro A; González-Barcia M; Gil-Martínez M; Santiago Varela M; Pardo M; Blanco-Méndez J; Piñeiro-Ces A; Lamas Díaz MJ; Otero-Espinar FJ
    Farm Hosp; 2016 Sep; 40(5):352-70. PubMed ID: 27570987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self assembling nanostructures for sustained ophthalmic drug delivery.
    Khopade AJ; Jain NK
    Pharmazie; 1995 Dec; 50(12):812-4. PubMed ID: 8584558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on the influence of auxiliary substances on the physico-chemical characteristics of ophthalmic drugs. Part I. Studies on the influence of auxiliary substances on the critical micellar concentration of surfactants solutions in eye drops containing sulphacetamidum natricum.
    Pluta J; Meler J
    Acta Pol Pharm; 2002; 59(4):247-52. PubMed ID: 12403298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of deep freezing on the stability of 25 mg/ml vancomycin ophthalmic solutions.
    Sautou-Miranda V; Libert F; Grand-Boyer A; Gellis C; Chopineau J
    Int J Pharm; 2002 Mar; 234(1-2):205-12. PubMed ID: 11839451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro elution of vancomycin/amikacin/steroid from solvent-free biodegradable scleral plugs.
    Liu SJ; Kau YC; Liaw CW; Peng YJ
    Int J Pharm; 2009 Mar; 370(1-2):75-80. PubMed ID: 19101617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Joint Intratracheal Surfactant-Antibacterial Therapy in Experimental Pseudomonas-Induced Pneumonia.
    Birkun AA; Kubyshkin AV; Novikov NY; Krivorutchenko YL; Fedosov MI; Postnikova ON; Snitser AA
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):299-307. PubMed ID: 25517041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and evaluation of pharmaceutical availability, stability and quality of modified viscosity eye drops with choline salicylate.
    Wróblewska KB; Plewa S; Długaszewska J; Froelich A; Muszalska-Kolos I
    Eur J Pharm Sci; 2021 Apr; 159():105725. PubMed ID: 33482319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Development of formulation of hipromellose eye drops (artificial tears)].
    Inkeniene AM; Klimas R; Briedis V; Maciulevicius J
    Medicina (Kaunas); 2003; 39(1):77-82. PubMed ID: 12576769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation of Carbopol 940 ophthalmic vehicles, and in vitro evaluation of the influence of simulated lacrimal fluid on their physico-chemical properties.
    Unlü N; Ludwig A; van Ooteghem M; Hincal AA
    Pharmazie; 1991 Nov; 46(11):784-8. PubMed ID: 1811229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability studies of five anti-infectious eye drops under exhaustive storage conditions.
    Curti C; Lamy E; Primas N; Fersing C; Jean C; Bertault-Peres P; Vanelle P
    Pharmazie; 2017 Dec; 72(12):741-746. PubMed ID: 29441959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use.
    Hartmann V; Keipert S
    Pharmazie; 2000 Jun; 55(6):440-3. PubMed ID: 10907252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient entrapment of amikacin and teicoplanin in liposomes.
    Ravaoarinoro M; Toma E; Agbaba O; Morisset R
    J Drug Target; 1993; 1(3):191-5. PubMed ID: 8069560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimental studies on topic application of amikacin to the eye (author's transl)].
    Krasemann C; Mester U; Stein HJ
    Arzneimittelforschung; 1978; 28(9):1602-4. PubMed ID: 582564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation.
    Belotti S; Rossi A; Colombo P; Bettini R; Rekkas D; Politis S; Colombo G; Balducci AG; Buttini F
    Eur J Pharm Biopharm; 2015 Jun; 93():165-72. PubMed ID: 25845771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amikacin-loaded vascular prosthesis as an effective drug carrier.
    Ginalska G; Kowalczuk D; Osińska M
    Int J Pharm; 2007 Jul; 339(1-2):39-46. PubMed ID: 17376617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives.
    Rojanarata T; Tankul J; Woranaipinich C; Potawanich P; Plianwong S; Sakulma S; Saehuan C
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):485-90. PubMed ID: 20879806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal delivery of aminoglycosides: amikacin transport and iontophoretic non-invasive monitoring.
    Nicoli S; Santi P
    J Control Release; 2006 Mar; 111(1-2):89-94. PubMed ID: 16413081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.